Osimertinib price after medical insurance reimbursement in 2024

Osimertinib (Tagrisso), as an anti-cancer drug that will still attract much attention in 2024, continues to bring hope to patients with non-small cell lung cancer (NSCLC). This drug is a third-generation EGFR tyrosine kinase inhibitor developed by AstraZeneca, specifically targeting patients with advanced non-small cell lung cancer with EGFR mutations. Especially for patients who have developed resistance after treatment with first- or second-generation EGFR inhibitors, osimertinib has shown significant therapeutic effects.

In the latest research progress, osimertinib has been continuously confirmed to be effective in the treatment of EGFR mutated NSCLC. Patients need to continue taking it as directed by their doctor until the disease progresses or intolerable side effects occur. The unique mechanism of osimertinib enables it to exert a powerful inhibitory effect against the T790M gene mutation, which often occurs in patients who are resistant to traditional EGFR inhibitors.

In addition to its significant therapeutic effect, osimertinib's side effects are relatively mild and can be tolerated by most patients. Common side effects include skin rash, nail discoloration, and diarrhea, but these symptoms are usually manageable. In addition, osimertinib is not affected by food and can be taken with food or on an empty stomach, providing patients with medication convenience.

In 2024, with the accumulation of more clinical data, osimertinib's position in the treatment of NSCLC will become increasingly stable. It not only prolongs the patient's survival, but more importantly improves the patient's quality of life. However, as with other anticancer drugs, the problem of drug resistance is gradually emerging. In this regard, researchers are constantly exploring new treatment options to address the challenge of drug resistance.

In general, osimertinib occupies an important position in the treatment of NSCLC due to its unique efficacy and relatively mild side effects. Osimertinib has now landed on the Chinese market and has been included in medical insurance, reducing the financial burden on patients. Each box of 80 mg and 30 pills costs only about 5,000 yuan with the help of medical insurance. At the same time, generic drugs have been launched in Laos, Bangladesh and other countries, with the same specifications of 80 mg and 30 pills, and the price is mostly between 600 and 1,000 yuan. The Laos Lucius version only costs about 590 yuan, while the Bangladesh Beacon version is slightly more expensive, about 2,400 yuan. For more information about osimertinib, it is recommended to consult a professional overseas medical consulting agency.